243 related articles for article (PubMed ID: 19875411)
1. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
[TBL] [Abstract][Full Text] [Related]
2. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
4. First case report of adalimumab-induced psoriasis in Crohn's disease.
Harris MD; Richards R
Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
[No Abstract] [Full Text] [Related]
5. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
6. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
West RL; Zelinkova Z; Wolbink GJ; Kuipers EJ; Stokkers PC; van der Woude CJ
Aliment Pharmacol Ther; 2008 Nov; 28(9):1122-6. PubMed ID: 18691349
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
9. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
Fanning SB; Chapman G; Yau Y; Leong RW
J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
[No Abstract] [Full Text] [Related]
10. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
11. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
12. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
[TBL] [Abstract][Full Text] [Related]
13. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
Hinojosa J; Gomollón F; García S; Bastida G; Cabriada JL; Saro C; Ceballos D; Peñate M; Gassull MA;
Aliment Pharmacol Ther; 2007 Feb; 25(4):409-18. PubMed ID: 17269996
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis during infliximab therapy for Crohn's disease.
Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
[TBL] [Abstract][Full Text] [Related]
17. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
18. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
[TBL] [Abstract][Full Text] [Related]
19. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
20. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
